Details for New Drug Application (NDA): 202603
✉ Email this page to a colleague
NDA 202603 describes METHOXSALEN, which is a drug marketed by Actavis Inc, Ani Pharms, and Strides Pharma, and is included in three NDAs. It is available from one supplier. Additional details are available on the METHOXSALEN profile page.
The generic ingredient in METHOXSALEN is methoxsalen. There are seven drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the methoxsalen profile page.
The generic ingredient in METHOXSALEN is methoxsalen. There are seven drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the methoxsalen profile page.
Summary for 202603
| Tradename: | METHOXSALEN |
| Applicant: | Actavis Inc |
| Ingredient: | methoxsalen |
| Patents: | 0 |
Medical Subject Heading (MeSH) Categories for 202603
Profile for product number 001
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | CAPSULE;ORAL | Strength | 10MG | ||||
| Approval Date: | Jun 9, 2015 | TE: | RLD: | No | |||||
Complete Access Available with Subscription
